Bile acids and incretins as modulators of obesity-associated atherosclerosis
Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841558804938883072 |
---|---|
author | Andrijana Kirsch Juergen Gindlhuber Diana Zabini Elena Osto Elena Osto |
author_facet | Andrijana Kirsch Juergen Gindlhuber Diana Zabini Elena Osto Elena Osto |
author_sort | Andrijana Kirsch |
collection | DOAJ |
description | Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies. |
format | Article |
id | doaj-art-e8f002bc80df4557882f50b54dec61be |
institution | Kabale University |
issn | 2297-055X |
language | English |
publishDate | 2025-01-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Cardiovascular Medicine |
spelling | doaj-art-e8f002bc80df4557882f50b54dec61be2025-01-06T05:13:19ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.15101481510148Bile acids and incretins as modulators of obesity-associated atherosclerosisAndrijana Kirsch0Juergen Gindlhuber1Diana Zabini2Elena Osto3Elena Osto4Division of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaDivision of Physiology and Pathophysiology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, AustriaVetsuisse Faculty, University of Zurich, Zurich, SwitzerlandObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide. Bile acids (BAs) and incretins are gut hormones involved in digestion and absorption of fatty acids, and insulin secretion, respectively. In recent years BAs and incretins are increasingly recognized as key signaling molecules, which target multiple tissues and organs, beyond the gastro-intestinal system. Moreover, incretin-based therapy has revolutionized the treatment of T2DM and obesity. This mini review highlights the current knowledge about dysregulations in BA homeostasis in obesity with a special focus on atherosclerosis as well as athero-modulating roles of incretins and currently available incretin-based therapies.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/fullcardiovascular diseaseobesitygut hormoneslipoproteinsatherosclerosis |
spellingShingle | Andrijana Kirsch Juergen Gindlhuber Diana Zabini Elena Osto Elena Osto Bile acids and incretins as modulators of obesity-associated atherosclerosis Frontiers in Cardiovascular Medicine cardiovascular disease obesity gut hormones lipoproteins atherosclerosis |
title | Bile acids and incretins as modulators of obesity-associated atherosclerosis |
title_full | Bile acids and incretins as modulators of obesity-associated atherosclerosis |
title_fullStr | Bile acids and incretins as modulators of obesity-associated atherosclerosis |
title_full_unstemmed | Bile acids and incretins as modulators of obesity-associated atherosclerosis |
title_short | Bile acids and incretins as modulators of obesity-associated atherosclerosis |
title_sort | bile acids and incretins as modulators of obesity associated atherosclerosis |
topic | cardiovascular disease obesity gut hormones lipoproteins atherosclerosis |
url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1510148/full |
work_keys_str_mv | AT andrijanakirsch bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis AT juergengindlhuber bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis AT dianazabini bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis AT elenaosto bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis AT elenaosto bileacidsandincretinsasmodulatorsofobesityassociatedatherosclerosis |